Latest Share Chat

REMOVE ADS

Physiomics Share News (PYC)

Physiomics Information

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes

Get Live Data

0.475 -0.025 (-5.00%)

Bid:

0.45

Ask:

0.50

Spread: 0.05 (11.111%)

Market Cap: £2.15m

Last checked at -

Intraday Physiomics Share Chart

REMOVE ADS

Mon, 07th Oct 2013 07:39

LONDON (Alliance News) - Physiomics PLC Monday said it has signed a contract with a new speciality pharmaceuticals customer to investigate how one of the client's new candidate drugs shrinks tumours.

Physiomics scientists will use systems biology approaches to map the possible pathways by which the drug could act, it said in a statement without giving any financial details. The analysis will be used to narrow down possible mechanisms and suggest new experiments that the client can perform to home in on one mechanism.

"If successful, the directors hope that Physiomics will be able to offer its other modelling services to this new client as the project progresses," the company said in a statement.

Physiomics shares were up 31.6% at 0.25 pence early Monday, the biggest gainer on AIM.

By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1